Search Results

PF-3758309 hydrochloride 2 mg  | 98.11%

TargetMol

PF-3758309, also known as PF-03758309, is a PAK4 inhibitor, is also a n orally bioavailable small-molecule inhibitor of p21-activated kinase 4 (PAK4) with potential antineoplastic activity. PAK4 inhibitor PF-03758309 binds to PAK4, inhibiting PAK4 activity and cancer cell growth. PAK4, a serine/threonine kinase belonging to the p21-activated kinase (PAK) family, is often upregulated in a […]

More Information Supplier Page

PF-06260933 2 mg  | Purity Not Available

TargetMol

PF-06260933 is a highly selective small-molecule MAP4K4 inhibitor with IC50s of 3.7 and 160 nM for kinase and cell, respectively.

More Information Supplier Page

E6446 1 mg  | 99.41%

TargetMol

E6446 inhibits Toll-like receptor (TLR)7 and 9 signaling. E6446 works in a variety of human and mouse cell types and inhibits DNA-TLR9 interaction in vitro. When administered to mice, this compound suppress responses to challenge doses of cytidine-phosphate-guanidine (CpG)-containing DNA, which stimulates TLR9.

More Information Supplier Page

Delamanid 100 mg  | Purity Not Available

TargetMol

Delamanid is an anti-tuberculosis agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis of bacterial cell wall.

More Information Supplier Page

Succinobucol 100 mg  | 98.80%

TargetMol

Succinobucol is a novel phenolic antioxidant small molecule with anti-oxidant and anti-inflammatory properties. It designed to treat atherosclerosis of the blood vessels of the heart or coronary artery disease.

More Information Supplier Page

AD80 1 mg  | 99.90%

TargetMol

AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.

More Information Supplier Page

Flumatinib 25 mg  | Purity Not Available

TargetMol

Flumatinib is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.

More Information Supplier Page